Danaher’s $9.9B Masimo Acquisition Triggers Masimo Removal from S&P MidCap 400
DHR•Danaher agreed in February to acquire Masimo at $180 per share in cash, valuing the deal at approximately $9.9 billion including debt. Masimo’s shares will be removed from the S&P MidCap 400 on June 11 before closing, after which it will operate as a standalone business within Danaher’s Diagnostics segment.
1. Acquisition Details
Danaher agreed in February to acquire Masimo for $180 per share in cash, valuing the transaction at roughly $9.9 billion including debt. Masimo shareholders approved the deal in May, and it is expected to close prior to June 10, subject to remaining regulatory clearances.
2. Index Impact
Masimo’s inclusion in the S&P MidCap 400 will end on June 11, with its shares suspended from trading that day. The removal is a direct result of the pending acquisition, and index-tracking funds will divest Masimo positions accordingly.
3. Integration Plan
Once the acquisition closes, Masimo will operate as a standalone business within Danaher’s Diagnostics segment. This structure aims to preserve Masimo’s brand and operational independence while leveraging Danaher’s global distribution and resources.
4. Strategic Rationale
The deal strengthens Danaher’s Diagnostics portfolio by adding Masimo’s patient-monitoring technology. The acquisition aligns with Danaher’s long-term strategy to expand high-growth life sciences and healthcare businesses.
